Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults

NCT02030275 is registered in ClinicalTrials.gov with RXi Pharmaceuticals, Corp. as lead sponsor.

NCT NCT02030275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02030275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults
Lead sponsor
RXi Pharmaceuticals, Corp.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
June 30, 2016
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic scar